Just say Hi from ASCO 2012
Discussion Board › Forums › Announcements › Just say Hi from ASCO 2012
- This topic has 20 replies, 6 voices, and was last updated 12 years, 5 months ago by pcl1029.
-
AuthorPosts
-
June 3, 2012 at 8:39 pm #61703pcl1029Member
Hi, everyone ,
today is the second day at the convention; to my surprise ,there are still no valid biomarker or test that either for prognosis or for predictive use for treatment.(ie;they are no NEGATIVE markers available to validate test or drug performances)and in some case ,poor performing tests produced differences and it cannot be fixed by retesting.
Another thing I found out is that ,in some cases,even they find out the targeted agent is useful for the tumor at first treatment; resistance occur later because the tumor develops newer pathway and therefore the targeted drug that was used is no longer works.
There are also ample evidences to indicate that the microenviroment around the tumor is of utmost importance to the survival of the tumor.The blood vessels,the lymphatic vessels;the matrix that between the two vessels systems and the antibodies that located nearby will all contribute to the effectiveness of the chemo and targeted agent treatment . In short,normalizing tumor microenviroment to treat the canner;using blood pressure medication(Losartin and others ARBs) to lower the interstitial fluid pressure for both the blood vessels and the lymphatic vessels;increase higher oxygenation to the affected areas will provide remarkable improvement in treatment efficacy including chemotherapy,radiation and immune therapy.
Dr. Rakesh Jain,the speaker from MGH who received the 2012 Science of Oncology award,also indicated that” in the next 5 years,there will be major developments in personalizing cancer therapy,using not only the genetic signature but also the microenviromental signature of cancer.” His team is searching for better normalizing drugs and seeking imaging , and /or tissue biomarkers that may help in the personalization of therapy.
His team included 200 doctoral and postdoctoral fellow across multiple disciplines and have produced 550 publications.
God bless.June 3, 2012 at 7:05 pm #61702jtoroMemberThanks for your update. Looking forward to hearing everything you learned.
God bless you.
JtoroJune 2, 2012 at 7:20 pm #61701gavinModeratorMany thanks for this Percy! Looking forward to hearing more from you as well. But remember to take some relaxation time for yourself as well! Hoping you all have a great conference! Thanks again.
Gavin
June 2, 2012 at 5:34 pm #61700darlaSpectatorThanks for the update Percy and thanks for being there. I too hope you have some relaxation time. Say hi to Marion and give her a big hug from me.
Darla
June 2, 2012 at 4:47 pm #61699lainySpectatorThank you PErcy, and am hoping you have some time to be relaxed and social and meet up with Marion. We so appreciate your being at ASCO.
June 2, 2012 at 4:19 pm #6906pcl1029MemberHi, everyone,
Nice to see karen in the first day at RAN; I have attended a few seminars for about 6 hours; the first one on new drugs that are recently approved by FDA or will be approved soon but NONE is for liver cancer or CCA. the names are Vemurafenib,Crizotinib,Brentuximab,Abiraterone,Ipilimumab,Axitinib and Vismodegib.
I will have a more detailed report after the convention. One thing I found out is that drugs that used on the patient does not always shows improvement of the disease state(ie; shrinkage of the tuorm) at the onset of the regimen;as a matter of fact ,for example the targeted drug called Ipilimumab(ILi) after the first two weeks of treatment ,PET scan shows increase in size of the tumor;but if the doctors do not stop the drug and continue to use it; in 6 month later,PET scan shows tumor shrinkage in size which is much smaller than before the start of the Ipilimumab. that is why as a patient,you have to be treated by oncologists who keep his/her knowledge up to date. (most of doctors will discontinue the treatment of Ipi after it shows increase in tumor size if he is not keep his/hers practice current.)
I have also attended a seminar talking about Liver mets; it is mostly based on the Barcelona scale. For unresectable liver cancer, they use TACE(ie;chemoembo);or Nexavar( sorafenib) for advance liver cancer; they also use Nexavar+TACE and found that if patients give Nexavar 7days BEFORE TACE treatment and continued afterward , the result is BETTER than give Nexavar AFTER TACE and continue on Nexavar.
Talk to all of you later.
God bless. -
AuthorPosts
- The forum ‘Announcements’ is closed to new topics and replies.